Detalhe da pesquisa
1.
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
Blood
; 142(6): 553-560, 2023 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37257195
2.
Dual-tracer PET/CT protocol with [18F]FDG and [68Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [18F]FDG in different cancer types, resulting in larger functional and gross tumor volume.
Strahlenther Onkol
; 200(1): 28-38, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584717
3.
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group.
Eur J Nucl Med Mol Imaging
; 51(2): 490-495, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37735258
4.
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Eur J Nucl Med Mol Imaging
; 51(5): 1361-1370, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114616
5.
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
Eur J Haematol
; 111(6): 881-887, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37644732
6.
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).
Br J Haematol
; 196(3): 606-616, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775591
7.
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Blood
; 136(25): 2851-2863, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33113552
8.
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
BMC Cancer
; 22(1): 672, 2022 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717166
9.
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).
Eur J Haematol
; 109(6): 728-735, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36056778
10.
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(2): 223-234, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539742
11.
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy.
Eur J Nucl Med Mol Imaging
; 48(1): 67-72, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33057773
12.
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.
Blood
; 132(21): 2273-2279, 2018 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30166329
13.
Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
Cochrane Database Syst Rev
; 1: CD012643, 2020 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31930780
14.
Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
Cochrane Database Syst Rev
; 9: CD012643, 2019 09 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31525824
15.
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Lancet
; 390(10114): 2790-2802, 2017 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29061295
16.
Defining the role of nuclear medicine in haematological tumours-EANM Focus 4: consensus on molecular imaging and therapy in haematological tumours.
Eur J Nucl Med Mol Imaging
; 50(10): 2925-2926, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37358621
17.
How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation.
Eur J Nucl Med Mol Imaging
; 51(1): 3-11, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37689611
18.
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
Lancet Oncol
; 18(4): 454-463, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28236583
19.
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Lancet Oncol
; 18(12): 1680-1687, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29133014
20.
Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
Br J Haematol
; 197(1): e5-e8, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34929056